On Thursday, Eli Lilly And Co (NYSE:LLY) reported second-quarter revenue of $11.3 billion, up 36% year over year, easily surpassing the consensus of $9.95 billion. The increase was driven by a 27% increase in volume and a 10% increase due to higher realized prices. The volume increase was primarily driven by growth from Mounjaro, Zepbound, Verzenio, Taltz and Jardiance, partially offset by the sale of rights for Baqsimi in Q2 2023 and declines in Trulicity. In its earnings release, Eli Lilly reported strong sales growth in its incretin medicines, driven by increased production that improved U.S. channel dynamics and stocking levels. Although supply and demand are now more balanced, the company anticipates potential supply constraints for ...